2-(8-(5-(4-cyclopentyl-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydropyrazino[1,2-a]indol-1-yl)acetic acid | 1262007-75-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(8-(5-(4-cyclopentyl-3-(trifluoromethyl)phenyl)-1,2,4-oxadiazol-3-yl)-1,2,3,4-tetrahydropyrazino[1,2-a]indol-1-yl)acetic acid
• 英文别名: 2-[8-[5-[4-Cyclopentyl-3-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-3-yl]-1,2,3,4-tetrahydropyrazino[1,2-a]indol-1-yl]acetic acid
• CAS: 1262007-75-9
• 化学式: C₂₇H₂₅F₃N₄O₃
• 分子量: 510.516
• InChiKey: YBYHZYJETQZIST-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  93.2
• 氢给体数：
  2
• 氢受体数：
  9

文献信息

• [EN] MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO<br/>[FR] MODULATEURS DU RÉCEPTEUR SPHINGOSINE-1-PHOSPHATE (S1P) UTILES POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS À CEUX-CI
  申请人：ARENA PHARM INC

  公开号：WO2011005295A1

  公开（公告）日：2011-01-13

  The present invention relates to certain compounds of Formula (Ia) and pharmaceutically acceptable salts, solvates, and hydrates thereof, which exhibit useful pharmacological properties, for example, as agonists of the S1P1 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of S1P1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, Crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type I diabetes, acne, myocardial ischemia-reperfusion injury, hypertensive nephropathy, glomerulosclerosis, gastritis, polymyositis, thyroiditis, vitiligo, hepatitis, biliary cirrhosis, microbial infections and associated diseases, viral infections and associated diseases, diseases and disorders mediated by lymphocytes, auto immune diseases, inflammatory diseases, and cancer.